tokens: Grouping tumors harboring a mutation in L2 / L3 together with CHEK2 mutations affecting kinase domain ( Arg95Ter ) in one group , mutations outside TP53 L2 / L3 and Ile364Thr as one group and tumors without any found mutations in TP53 and CHEK2 separately , again no noticeably difference in relapse - free survival were seen ( Figure 1C ) .